These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 36315597)

  • 21. An update on benznidazole for the treatment of patients with Chagas disease.
    Thakare R; Dasgupta A; Chopra S
    Drugs Today (Barc); 2018 Jan; 54(1):15-23. PubMed ID: 29569658
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Response to chemotherapy with benznidazole of clones isolated from the 21SF strain of Trypanosoma cruzi (biodeme Type II, Trypanosoma cruzi II).
    Campos RF; Guerreiro ML; Sobral Kde S; Lima Rde C; Andrade SG
    Rev Soc Bras Med Trop; 2005; 38(2):142-6. PubMed ID: 15821788
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Parasitaemia and parasitic load are limited targets of the aetiological treatment to control the progression of cardiac fibrosis and chronic cardiomyopathy in Trypanosoma cruzi-infected dogs.
    Caldas IS; Menezes APJ; Diniz LF; Nascimento ÁFDSD; Novaes RD; Caldas S; Bahia MT
    Acta Trop; 2019 Jan; 189():30-38. PubMed ID: 30290285
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low-dose of benznidazole promotes therapeutic cure in experimental chronic Chagas' disease with absence of parasitism in blood, heart and colon.
    Perin L; Fonseca KDS; de Carvalho TV; Carvalho LM; Madeira JV; Medeiros LDF; Molina I; Correa-Oliveira R; Carneiro CM; Vieira PMA
    Exp Parasitol; 2020 Mar; 210():107834. PubMed ID: 31978394
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 4-aminopyridyl-based lead compounds targeting CYP51 prevent spontaneous parasite relapse in a chronic model and improve cardiac pathology in an acute model of Trypanosoma cruzi infection.
    Calvet CM; Choi JY; Thomas D; Suzuki B; Hirata K; Lostracco-Johnson S; de Mesquita LB; Nogueira A; Meuser-Batista M; Silva TA; Siqueira-Neto JL; Roush WR; de Souza Pereira MC; McKerrow JH; Podust LM
    PLoS Negl Trop Dis; 2017 Dec; 11(12):e0006132. PubMed ID: 29281643
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nifurtimox versus benznidazole or placebo for asymptomatic Trypanosoma cruzi infection (Equivalence of Usual Interventions for Trypanosomiasis - EQUITY): study protocol for a randomised controlled trial.
    Villar JC; Herrera VM; Pérez Carreño JG; Váquiro Herrera E; Castellanos Domínguez YZ; Vásquez SM; Cucunubá ZM; Prado NG; Hernández Y
    Trials; 2019 Jul; 20(1):431. PubMed ID: 31307503
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trypanosoma cruzi: Induction of benznidazole resistance in vivo and its modulation by in vitro culturing and mice infection.
    Dos Santos FM; Caldas S; de Assis Cáu SB; Crepalde GP; de Lana M; Machado-Coelho GL; Veloso VM; Bahia MT
    Exp Parasitol; 2008 Dec; 120(4):385-90. PubMed ID: 18823980
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trypanosoma cruzi: acute and long-term infection in the vertebrate host can modify the response to benznidazole.
    Caldas S; Santos FM; de Lana M; Diniz LF; Machado-Coelho GL; Veloso VM; Bahia MT
    Exp Parasitol; 2008 Mar; 118(3):315-23. PubMed ID: 17945216
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thioridazine aggravates skeletal myositis, systemic and liver inflammation in Trypanosoma cruzi-infected and benznidazole-treated mice.
    Mendonça AAS; Gonçalves-Santos E; Souza-Silva TG; González-Lozano KJ; Caldas IS; Gonçalves RV; Diniz LF; Novaes RD
    Int Immunopharmacol; 2020 Aug; 85():106611. PubMed ID: 32447223
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of continuous versus intermittent administration of nanoformulated benznidazole during the chronic phase of Trypanosoma cruzi Nicaragua infection in mice.
    Rial MS; Arrúa EC; Natale MA; Bua J; Esteva MI; Prado NG; Laucella SA; Salomon CJ; Fichera LE
    J Antimicrob Chemother; 2020 Jul; 75(7):1906-1916. PubMed ID: 32274510
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Promising Efficacy of Benznidazole Nanoparticles in Acute Trypanosoma cruzi Murine Model: In-Vitro and In-Vivo Studies.
    Scalise ML; Arrúa EC; Rial MS; Esteva MI; Salomon CJ; Fichera LE
    Am J Trop Med Hyg; 2016 Aug; 95(2):388-93. PubMed ID: 27246447
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessing the Effectiveness of Curative Benznidazole Treatment in Preventing Chronic Cardiac Pathology in Experimental Models of Chagas Disease.
    Francisco AF; Jayawardhana S; Taylor MC; Lewis MD; Kelly JM
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30082291
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Benznidazole treatment following acute Trypanosoma cruzi infection triggers CD8+ T-cell expansion and promotes resistance to reinfection.
    Olivieri BP; Cotta-De-Almeida V; Araújo-Jorge T
    Antimicrob Agents Chemother; 2002 Dec; 46(12):3790-6. PubMed ID: 12435678
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized trial of posaconazole and benznidazole for chronic Chagas' disease.
    Molina I; Gómez i Prat J; Salvador F; Treviño B; Sulleiro E; Serre N; Pou D; Roure S; Cabezos J; Valerio L; Blanco-Grau A; Sánchez-Montalvá A; Vidal X; Pahissa A
    N Engl J Med; 2014 May; 370(20):1899-908. PubMed ID: 24827034
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment with Fenofibrate plus a low dose of Benznidazole attenuates cardiac dysfunction in experimental Chagas disease.
    Cevey ÁC; Mirkin GA; Donato M; Rada MJ; Penas FN; Gelpi RJ; Goren NB
    Int J Parasitol Drugs Drug Resist; 2017 Dec; 7(3):378-387. PubMed ID: 29040909
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Course of Chronic Trypanosoma cruzi Infection after Treatment Based on Parasitological and Serological Tests: A Systematic Review of Follow-Up Studies.
    Sguassero Y; Cuesta CB; Roberts KN; Hicks E; Comandé D; Ciapponi A; Sosa-Estani S
    PLoS One; 2015; 10(10):e0139363. PubMed ID: 26436678
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Benznidazole/Poloxamer 407 Solid Dispersion as a New Strategy to Improve the Treatment of Experimental Trypanosoma cruzi Infection.
    Davies C; Simonazzi A; Micheloud JF; Ragone PG; Cid AG; Negrette OS; Bermúdez JM; Parada LA
    J Parasitol; 2020 Jun; 106(3):323-333. PubMed ID: 32369594
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New Scheme of Intermittent Benznidazole Administration in Patients Chronically Infected with Trypanosoma cruzi: Clinical, Parasitological, and Serological Assessment after Three Years of Follow-Up.
    Álvarez MG; Ramírez JC; Bertocchi G; Fernández M; Hernández Y; Lococo B; Lopez-Albizu C; Schijman A; Cura C; Abril M; Laucella S; Tarleton RL; Natale MA; Castro Eiro M; Sosa-Estani S; Viotti R
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32571827
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo selection of a population of Trypanosoma cruzi and clones resistant to benznidazole.
    Murta SM; Romanha AJ
    Parasitology; 1998 Feb; 116 ( Pt 2)():165-71. PubMed ID: 9509026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Decreased intensity of inflammation in benznidazole-treated mice inoculated with Trypanosoma cruzi I stocks from Mexico and persistence of circulating parasites.
    Cruz-Zetina G; del Rio-Rodriguez R; Ramos-Ligonio A; López R; Monteon V
    Am J Trop Med Hyg; 2012 Oct; 87(4):671-4. PubMed ID: 22890036
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.